Szanya J. Predictive morphological findings in "zero-hour" biopsies of renal allografts.. (1997) ACTA CHIRURGICA HUNGARICA 0231-4614 36 1-4 346-348,
1434364
Szakcikk (Folyóiratcikk) | Tudományos[1434364]
Pegas K et al. Histological analysis of pre-transplant deceased donor renal biopsies and its association with long-term graft survival and function. (2018) JOURNAL OF NEPHROPATHOLOGY 2251-8363 2251-8819 7 4 248-254
Rathore RS et al. Can zero-hour cortical biopsy predict early graft outcomes after living donor renal transplantation?. (2017) CANADIAN UROLOGICAL ASSOCIATION JOURNAL 1911-6470 1920-1214 11 11 E437-E440
Yildiz S et al. Mesangial IgA deposition in zero-hour graft biopsy: Two cases. (2016) TURKISH NEPHROLOGY, DIALYSIS AND TRANSPLANTATION JOURNAL = TURK NEFROLOJI DIYALIZ VE TRANSPLANTASYON DERGISI 1300-7718 25 3 313-316
Wang C et al. The Donor Kidney Biopsy and Its Implications in Predicting Graft Outcomes: A Systematic Review. (2015) AMERICAN JOURNAL OF TRANSPLANTATION 1600-6135 1600-6143 15 7 1903-1914
Kasiske BL et al. The Role of Procurement Biopsies in Acceptance Decisions for Kidneys Retrieved for Transplant. (2014) CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 1555-9041 1555-905X 9 3 562-571
Tsuchimoto A et al. Renal Interstitial Fibrosis in 0-Hour Biopsy as a Predictor of Post-Transplant Anemia. (2013) AMERICAN JOURNAL OF NEPHROLOGY 0250-8095 1421-9670 38 4 267-274
Woestenburg A et al. Vasculopathy in the kidney allograft at time of transplantation: Impact on later function of the graft. (2008) TRANSPLANTATION 0041-1337 85 7 S10-S18
Jain M et al. Significance of „zero-hour” graft biopsy in live related renal allograft recipients. (2003) Indian Journal of Nephrology 0971-4065 1998-3662 13 98-103
Kiser RL et al. Preexisting crescentic glomerulonephritis in the renal allograft. (2003) AMERICAN JOURNAL OF KIDNEY DISEASES 0272-6386 1523-6838 42 5 p. E23
Freedland S et al. Effective renal plasma flow calculated from a single blood sample following technetium-99m mercaptoacetyltriglycine renal scan can predict delayed graft function in renal transplantation. (2001) Techniques in Urology 1079-3259 7 4 281-284
Sen S. Morphological findings of zero hour needle biopsies and their influence on early graft function. (2000) Office Journal of the Turkish Nephrology 1 30-36
Bosmans JL et al. Fibrous intimal thickening at implantation as a risk factor for the outcome of cadaveric renal allografts. (2000) TRANSPLANTATION 0041-1337 69 11 2388-2394
Malaise J et al. Baseline biopsy for the quality assessment of kidney graft. (1999) CURRENT OPINION IN ORGAN TRANSPLANTATION 1087-2418 1531-7013 4 p. 139
Szakaly P. Null-biopszia klinikai értéke vesetranszplantációban. (2001) MAGYAR SEBÉSZET 0025-0295 1789-4301 54 1 18-22,
1434359
Szakcikk (Folyóiratcikk) | Tudományos[1434359]
Lubuska L et al. ASSESSMENT OF RENAL GRAFT FUNCTION DEPENDING ON PRE-TRANSPLANT MORPHOLOGY. (2006) BIOMEDICAL PAPERS-OLOMOUC 1213-8118 1804-7521 150 171-177
FTY720 2218 Clinical Study Group [Kollaborációs szervezet] et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: Six-month results of a double-blind study. (2007) TRANSPLANTATION 0041-1337 84 7 885-892,
1761500
Sokszerzős vagy csoportos szerzőségű szakcikk (Folyóiratcikk) | Tudományos[1761500]
McGinley Marisa P. et al. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. (2021) LANCET 0140-6736 1474-547X 398 10306 1184-1194
Tehrani M.B. et al. Spectrophotometric determination of fingolimod in pharmaceutical dosage forms. (2019) ASIAN JOURNAL OF CHEMISTRY 0970-7077 0975-427X 31 1 157-160
Chun Jerold et al. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders. (2019) Megjelent: ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59 pp. 149-170
Ueda Norishi. Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases. (2017) CURRENT MEDICINAL CHEMISTRY 0929-8673 1875-533X 24 12 1238-1275
Tian T et al. FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF- signalling in fibroblasts. (2017) CLINICAL AND EXPERIMENTAL IMMUNOLOGY 0009-9104 1365-2249 190 1 68-78
Chew Wee Siong et al. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling. (2016) PHARMACOLOGICAL RESEARCH 1043-6618 1096-1186 113 521-532
Pul Refik et al. Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?. (2016) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 17 12
Koch Martina et al. Effects of FTY720 on peripheral blood lymphocytes and graft infiltrating cells in a rat model of chronic renal allograft rejection. (2016) TRANSPLANT IMMUNOLOGY 0966-3274 35 12-17
Gholamnezhadjafari Reza et al. Effect of FTY720 (fingolimod) on graft survival in renal transplant recipients: a systematic review protocol. (2016) BMJ OPEN 2044-6055 6 4
Enjeti Anoop K et al. A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. (2016) ANTI-CANCER DRUGS 0959-4973 1473-5741 27 6 560-568
David Olivier J et al. Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study. (2015) INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 0946-1965 53 10 847-854
Ranghino Andrea et al. Lymphatic disorders after renal transplantation: new insights for an old complication. (2015) NEPHROLOGY DIALYSIS TRANSPLANTATION PLUS (NDT PLUS ) 1753-0784 1753-0792 8 5 615-622
Souri E. et al. A stability-indicating HPLC method for the determination of fingolimod in pharmaceutical dosage forms. (2015) SCIENTIA PHARMACEUTICA 0036-8709 2218-0532 83 1 85-93
Randhawa P.. Mechanistic Aspects of Cell-Mediated Rejection. (2014) Megjelent: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms pp. 639-649
Koscielny A et al. The role of lymphoid tissue in the attenuation of the postoperative ileus. (2013) AMERICAN JOURNAL OF PHYSIOLOGY: GASTROINTESTINAL AND LIVER PHYSIOLOGY 0193-1857 1522-1547 304 4 401-412
Alshaker Heba et al. Therapeutic Potential of Targeting SK1 in Human Cancers. (2013) Megjelent: ROLE OF SPHINGOLIPIDS IN CANCER DEVELOPMENT AND THERAPY pp. 143-200
Pereira FV et al. FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. (2013) CLINICS 1807-5932 1980-5322 68 7 1018-1027
Ontaneda D et al. Early tolerability and safety of fingolimod in clinical practice. (2012) JOURNAL OF THE NEUROLOGICAL SCIENCES 0022-510X 1878-5883 323 1-2 167-172
Ontaneda D et al. Benefits versus risks of latest therapies in multiple sclerosis: A perspective review. (2012) THERAPEUTIC ADVANCES IN DRUG SAFETY 2042-0986 2042-0994 3 6 291-303
Müller H C et al. The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. (2011) PULMONARY PHARMACOLOGY & THERAPEUTICS 1094-5539 1522-9629 24 4 377-385
Silva HT et al. The Emerging Role of Brazil in Clinical Trial Conduct for Transplantation. (2011) AMERICAN JOURNAL OF TRANSPLANTATION 1600-6135 1600-6143 11 7 1368-1375
Blaho Victoria A et al. Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors. (2011) CHEMICAL REVIEWS 0009-2665 1520-6890 111 10 6299-6320
Ettenger R et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants. (2011) PEDIATRIC TRANSPLANTATION 1397-3142 1399-3046 15 4 406-413
Medina-Pestana José O. et al. Kidney transplantation in Brazil and its geographic disparity. (2011) JORNAL BRASILEIRO DE NEFROLOGIA 0101-2800 2175-8239 33 4 472-484
Hoitsma AJ et al. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. (2011) NEPHROLOGY DIALYSIS TRANSPLANTATION 0931-0509 1460-2385 26 11 3802-3805
Chiang ET et al. Acute Lung Injury: The Injured Lung Endothelium, Therapeutic Strategies for Barrier Protection, and Vascular Biomarkers. (2011) Megjelent: TEXTBOOK OF PULMONARY VASCULAR DISEASE pp. 197-222
White CA et al. Use of Kidney Function End Points in Kidney Transplant Trials: A Systematic Review. (2010) AMERICAN JOURNAL OF KIDNEY DISEASES 0272-6386 1523-6838 56 6 1140-1157
Shea Barry S et al. Prolonged Exposure to Sphingosine 1-Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury. (2010) AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY 1044-1549 1535-4989 43 6 662-673
Li Q et al. Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats. (2010) IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 0892-3973 1532-2513 32 4 680-687
Sensken S et al. Down-regulation of S1P1 receptor surface expression by protein kinase C inhibition. (2010) JOURNAL OF BIOLOGICAL CHEMISTRY 0021-9258 1083-351X 285 9 6298-6307
Schwarz A et al. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. (2010) NEUROLOGY 0028-3878 1526-632X 74 24 2022-2024
Foucher Y et al. A clinical scoring system highly predictive of long-term kidney graft survival. (2010) KIDNEY INTERNATIONAL 0085-2538 1523-1755 78 12 1288-1294
Wolfson RK et al. Therapeutic Strategies to Limit Lung Endothelial Cell Permeability. (2009) Megjelent: The Pulmonary Endothelium: Function in health and disease pp. 337-354
Camp S M et al. Synthetic Analogs of FTY720 [2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] Differentially Regulate Pulmonary Vascular Permeability in Vivo and in Vitro. (2009) JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 0022-3565 1521-0103 331 1 54-64
Ishii M et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. (2009) NATURE 0028-0836 1476-4687 458 7237 524-528
Kumar A et al. Lyase to live by: Sphingosine phosphate lyase as a therapeutic target. (2009) EXPERT OPINION ON THERAPEUTIC TARGETS 1472-8222 1744-7631 13 8 1013-1025
Zhou P J et al. Immunomodulatory drug FTY720 induces regulatory CD4+CD25 + T cells in vitro. (2009) CLINICAL AND EXPERIMENTAL IMMUNOLOGY 0009-9104 1365-2249 157 1 40-47
Lynch Kevin R et al. Sphingosine 1-phosphate chemical biology. (2008) BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS 1388-1981 1879-2618 1781 9 508-512
Yuan W et al. Cyclosporin A effects on expressions of tumor necrosis factor-related apoptosis-inducing ligand and death receptor 4 in rat corneal allografts during acute rejection phase. (2008) JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH / ZHONG GUO ZU ZHI GONG CHENG YAN JIU YU LIN CHUANG KANG FU 1673-8225 12 18 3453-3456
Sułowicz W et al. Discontinuation of mycophenolate mofetil from a tacrolimus-based triple regimen 2 months after renal transplantation: A comparative randomized multicentre study. (2007) TRANSPLANT INTERNATIONAL 0934-0874 1432-2277 20 3 230-237,
1761501
Szakcikk (Folyóiratcikk) | Tudományos[1761501]
Vanhove T et al. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. (2013) TRANSPLANT INTERNATIONAL 0934-0874 1432-2277 26 8 813-821
Szakály P et al. Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia-reperfusion. (2008) JOURNAL OF MOLECULAR NEUROSCIENCE 0895-8696 1559-1166 36 1-3 89-96,
1159013
Szakcikk (Folyóiratcikk) | Tudományos[1159013]
Eiden Lee E. et al. Regulatory peptides and systems biology: A new era of translational and reverse‐translational neuroendocrinology. (2020) JOURNAL OF NEUROENDOCRINOLOGY 0953-8194 1365-2826 32 5
Hajji Khadija et al. Neuroprotective effects of PACAP against paraquat-induced oxidative stress in the Drosophila central nervous system. (2019) HUMAN MOLECULAR GENETICS 0964-6906 1460-2083 28 11 1905-1918
Eneman Benedicte et al. Distribution and Function of PACAP and Its Receptors in the Healthy and Nephrotic Kidney. (2016) NEPHRON (2015-) 1660-8151 2235-3186 0028-2766 132 4 301-311
Herrera Victoria L et al. Worse Renal Disease in Postmenopausal F2[Dahl S x R]-Intercross Rats: Detection of Novel QTLs Affecting Hypertensive Kidney Disease. (2013) PLOS ONE 1932-6203 8 2
Eiden LE. PACAP and cellular protection: Cellular protection by members of the VIP/secretin family with emphasis on pituitary adenylate cyclase activating polypeptide (PACAP). (2012) Megjelent: Neuropeptides in Neuroprotection and Neuroregeneration pp. 179-208
Khan A.-M. et al. Renoprotection with pituitary adenylate cyclase-activating polypeptide in cyclosporine A-induced nephrotoxicity. (2011) Journal of Investigative Medicine 1708-8267 59 5 793-802
Ison MG et al. Oseltamivir prophylaxis significantly reduces the incidence of seasonal influenza infection in immunocompromised patients. (2009) Megjelent: 11th International Symposium Respiratory Viral Infections pp. 33-34,
2329338
Shah Dimpy P et al. Management of respiratory viral infections in hematopoietic cell transplant recipients. (2012) AMERICAN JOURNAL OF BLOOD RESEARCH 2160-1992 2 4 203-218
Gainer Sarah M et al. Increased mortality of solid organ transplant recipients with H1N1 infection: a single center experience. (2012) CLINICAL TRANSPLANTATION 0902-0063 1399-0012 26 2 229-237
Lam H et al. Oseltamivir, an Influenza Neuraminidase Inhibitor Drug, Does Not Affect the Steady-State Pharmacokinetic Characteristics of Cyclosporine, Mycophenolate, or Tacrolimus in Adult Renal Transplant Patients. (2011) THERAPEUTIC DRUG MONITORING 0163-4356 33 6 699-704
Zapata Rodrigo et al. Severe novel H1N1 influenza A infection in the immediate postoperative period of a liver transplant patient. (2010) LIVER TRANSPLANTATION 1527-6465 1527-6473 16 4 447-452
Gil Redelman-Sidi. Influenza in patients with hematologic disease: an ounce of prevention is worth a pound of cure. (2010) LEUKEMIA & LYMPHOMA 1042-8194 1029-2403 51 11 1954-1956